Tag Archives: low-density lipoprotein (LDL)

Introduction Low-density lipoprotein-cholesterol (LDL-C) is accepted as a causal risk factor for development of atherosclerotic cardiovascular disease (CVD) and acute coronary syndromes (ACS).1 European Society of Cardiology (ESC) guidelines have been extensive in setting up lipid targets for primary and secondary prevention of CVD.2 The 2021 ESC guidelines carry forward the 2019 ESC dyslipidaemia targets to introduce a therapeutic regimen that achieves a ≥50% LDL-C reduction from baseline and a LDL-C goal of <1.4 mmol/L (<55 mg/dL) (very-high-risk group) or <1.8 mmol/L (high-risk group).2 The updated National Institute for Health

Introduction Statins are the gold-standard lipid-lowering therapy based on their efficacy in reducing serum low-density lipoprotein cholesterol (LDL-C) and general tolerability.1 While statins have an extensive body of evidence that have shown them to reduce the risk of cardiovascular (CV) events,2,3 there are concerns around side effects. An increase in cases of treatment-induced comorbidities, such as new-onset diabetes mellitus (NODM) has been observed.4-6 When combined with patient and media concerns, this has led to a reported 50% drop-out rate within 12 months.1 In response, other LDL-C lowering medications have been developed. Proprote